Home › Cutaneous T-Cell Lymphoma
Cutaneous T-Cell Lymphoma clinical trials recruiting in the U.S.
30 studies for Cutaneous T-Cell Lymphoma are recruiting participants at sites across the United States.
Cities with the most studies
- New York City, NY9 studies
- Baldwin Park, CA8 studies
- Houston, TX5 studies
- Boston, MA5 studies
- New Haven, CT4 studies
- Durham, NC3 studies
- Chicago, IL3 studies
- Ann Arbor, MI3 studies
- Columbus, OH3 studies
- Tampa, FL3 studies
- Rochester, MN3 studies
- Scottsdale, AZ3 studies
By state
- Arizona3 studies
- California8 studies
- Connecticut4 studies
- Florida3 studies
- Illinois3 studies
- Massachusetts5 studies
- Michigan3 studies
- Minnesota3 studies
- New York10 studies
- North Carolina3 studies
- Ohio4 studies
- Pennsylvania4 studies
- Texas5 studies
Recently updated studies
Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment
RecruitingObservational studyHealthy volunteers welcome
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT01087333A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 15, 2026 · NCT07195916A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 9, 2026 · NCT06854653Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 2, 2026 · NCT04930653A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)
RecruitingPhase 1
Ages 18 to 120 · All sexes · Updated Aug 24, 2026 · NCT07055477A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 21, 2026 · NCT07192471Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 31, 2026 · NCT03011814A Pilot of a Microdevice For In Situ Candidate Drug Screening in Cutaneous Lesions of T-Cell Lymphoma
Recruiting
Ages 18 and older · All sexes · Updated Jul 27, 2026 · NCT04045470A Phase 2 Trial to Assess Safety and Efficacy of Tofacitinib 2% Cream in the Treatment of Cutaneous T-cell Lymphoma (CTCL), Stages IA, IB, and IIA
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 13, 2026 · NCT06698822Combating Cancer-Related Fatigue: A Personalized Supportive Care Program
Recruiting
Ages 18 and older · All sexes · Updated Jul 1, 2026 · NCT06860880Registry of Older Patients With Cancer
RecruitingObservational study
Ages 65 and older · All sexes · Updated Jun 29, 2026 · NCT01137825Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jun 11, 2026 · NCT05313243A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 10, 2026 · NCT03017820A Registry for People With T-cell Lymphoma
RecruitingObservational study
All ages · All sexes · Updated May 20, 2026 · NCT05978141Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas
RecruitingPhase 2
Ages 18 and older · All sexes · Updated May 5, 2026 · NCT05956041Characterization of the Microbiome in Cutaneous T Cell Lymphoma
RecruitingObservational studyHealthy volunteers welcome
Ages 18 to 89 · All sexes · Updated May 1, 2026 · NCT03932279Photopheresis in Early-stage Mycosis Fungoides
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Apr 27, 2026 · NCT05680558Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Apr 15, 2026 · NCT07356245Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Apr 14, 2026 · NCT05996185Ropeginterferon in Patients w/Cutaneous T-Cell Lymphoma (CTCL)
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Apr 1, 2026 · NCT07047885Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Feb 10, 2026 · NCT04848064A Study of Bexarotene Combined With Radiotherapy in People With Mycosis Fungoides
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Feb 4, 2026 · NCT05296304Quality of Life in Cutaneous Lymphoma Patients Using the Skindex29
RecruitingObservational study
Ages 18 and older · All sexes · Updated Jan 28, 2026 · NCT04670874Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
RecruitingObservational study
Ages 18 and older · All sexes · Updated Dec 30, 2025 · NCT00177268Amping up With PemJAK
RecruitingPhase 2
Ages 18 to 95 · All sexes · Updated Dec 16, 2025 · NCT07283822From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.